Bone Grafts Research Today is a free monthly online journal that collates and summarizes the latest research about Bone Grafts, including details on spine fusion, surgery, procedure, risks.

Limitations of intravenous human bone marrow CD133+ cell grafts in stroke rats.

Borlongan CV, Evans A, Yu G, Hess DC

Department of Neurology, BI-3080, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912-3200, USA. cborlongan@mail.mcg.edu

We examined the effects of timing and routes of transplantation on survival and functional benefits of human bone-marrow-derived CD133+ cells in experimentally stroke Sprague-Dawley rats. At day 7 post-stroke, both immediate and delayed intracerebral transplantation resulted in similar graft survival (7%) that was localized within the original transplant site and reduction of motor (27%) and neurological (40%) deficits. In contrast, graft survival (0.01-0.04%) was only detected in delayed intravenous transplantation, characterized by cell migration throughout the ipsilateral stroke hemisphere. Behavioral improvement, however, was limited to neurological response and only apparent in immediate intravenous transplantation. Reduction of cerebral infarct (25%) was only noted in intracerebral transplantation. Intravenous transplantation requires optimization for improved therapeutic outcome of CD133+ cell grafts in stroke.

Published 17 June 2005 in Brain Res, 1048(1): 116-22.
Full-text of this article is available online (may require subscription).

© 2004-2008 Bone Grafts Research Today. All Rights Reserved.